Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Business https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ FDA approves new weight loss medication

FDA approves new weight loss medication

The US Food and Drug Administration (FDA) has approved a new drug that can be used as a weight loss drug.

Wegovy is specifically designed for chronic weight management in obese or overweight adults with “at least one weight-related comorbidity”, according to pharmaceutical company Novo Nordisk, the manufacturer of the drug. Wegovy is a higher dose of Novos diabetes medicine semaglutide.

In company-funded studies, participants taking Wegovy had an average weight loss of 1

5%, approx. 34 pounds (15.3 kg). Participants lost steadily for 14 months before becoming the plateau. In a comparison group that received dummy shots, the average weight loss was approx. 2.5% or just under 6 pounds.

In particular, Novo’s anti-obesity medication is said to induce weight loss in patients by reducing hunger while increasing the feeling of fullness.


The drug, which is injected by the patient once a week, is intended to be used in addition to diet and exercise, according to Novo.

A four-week delivery of Wegovy, which is essentially four injections, will cost consumers around $ 1,300.

The product is available on prescription from a healthcare professional and is scheduled to be available at pharmacies later this month.

GET FOX BUSINESS ON SPEED by clicking here

“Despite the best efforts to lose weight, many people struggle with obesity to achieve and maintain weight loss due to physiological responses that favor weight gain,” said Martin Holst Lange, Novo Nordisk’s Executive Vice President of Development.

According to Lange, it marks “a new era in the treatment of obesity.”

The Associated Press contributed to this report

Source link